Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Sanara MedTech Inc. Chief Executive Officer Yon Seth D reported an automatic share withholding related to equity compensation. On the vesting of 13,466 shares of restricted stock, 3,852 shares of common stock were withheld by the company to satisfy tax withholding obligations, based on a value of $21.06 per share. No shares were issued or sold in this transaction, and following the withholding, the CEO directly holds 109,546 shares of common stock.
Sanara MedTech Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $27,798,534 from $23,434,096 a year earlier, driven mainly by growth in soft tissue repair products. Gross profit increased to $25,874,945, while operating income improved to $2,646,581.
The company generated net income of $458,603, or $0.05 per diluted share, compared with a net loss of $3,527,383 in the prior-year quarter, helped by small income from discontinued THP operations. Cash declined to $13,594,459 as net cash used in operating activities was $2,465,407. Long-term debt under the CRG term loan was $46,226,422.
Sanara MedTech Inc. reported strong first quarter 2026 results with higher growth and a swing to profitability. Net revenue rose 19% to $27.8 million, driven mainly by a 21% increase in soft tissue repair product sales, while bone fusion revenue was slightly lower.
Gross profit reached $25.9 million with a 93% margin, up from 92%. Operating income more than tripled to $2.6 million. Net income from continuing operations was $0.4 million, or $0.04 per diluted share, compared with a loss a year earlier, and total net income was $0.46 million. Adjusted EBITDA increased 58% to $4.3 million, reflecting operating leverage despite higher selling and marketing costs.
Sanara ended March 31, 2026 with $13.6 million in cash and $46.2 million of long-term debt. The company guided second quarter 2026 net revenue to $28.5–$29.5 million (10–14% growth) and reaffirmed full-year 2026 net revenue guidance of $116–$121 million, implying 13–17% growth over 2025.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of restricted common stock at no cash cost under the company’s 2024 Omnibus Long-Term Incentive Plan. The restricted stock vests in three equal installments on March 22 of 2027, 2028 and 2029, if she remains employed on each date.
The amended Form 4 corrects her post‑grant holdings to 4,967 common shares, revising an earlier filing that had overstated the amount as 5,067 shares.
Sanara MedTech Inc. is holding its 2026 annual shareholder meeting virtually on June 4, 2026 at 10:00 a.m. Central Time. Holders of 9,164,757 common shares outstanding as of April 8, 2026 may vote on electing nine directors, ratifying Weaver and Tidwell, L.L.P. as auditor, and two advisory votes on executive compensation and its future frequency.
The Board recommends voting for all director nominees, for auditor ratification and say-on-pay, and selecting three years for future advisory pay votes. The proxy also details corporate governance practices, director pay in cash and restricted stock, and concentrated ownership led by Executive Chairman Ronald T. Nixon.
Sanara MedTech Inc. reported a routine equity compensation event for Chief Operating Officer Jacob A. Waldrop. As 1,551 shares of previously granted restricted stock vested, 378 shares of common stock were withheld by the company to satisfy tax withholding obligations. The filing states that no shares were issued or sold in this transaction. Following the tax withholding disposition, Waldrop directly holds 24,377 shares of Sanara MedTech Inc. common stock.
Sanara MedTech Inc. beneficial ownership disclosure: Baird Trust Company, Baird Financial Corporation and Baird Financial Group, Inc. report aggregated beneficial ownership of 21,075 shares of Common Stock. The filing bases the percentage on 9,167,040 Shares outstanding as of March 20, 2026.
The reporting persons state the shares reflect shared voting and dispositive power held by Baird Trust Company on behalf of clients. Ownership is reported as 5% or less of the class.
Sanara MedTech Inc. reports on its business for the year ended December 31, 2025 as a medical technology company focused on surgical wound care and bone fusion products sold primarily to U.S. hospitals and surgical centers.
The company discontinued its Tissue Health Plus value-based wound care program in mid-September 2025 after persistent losses and unsuccessful efforts to secure outside investment, and now operates as a single surgical-focused segment with THP reported as discontinued operations.
Key products include CellerateRX Surgical hydrolyzed collagen, BIASURGE surgical irrigation, and ALLOCYTE Plus cellular bone matrix, supported by preclinical, clinical and health-economic studies showing improved wound outcomes and modeled cost savings per high-risk spinal patient.
Sanara highlights differentiated surgical technologies, a U.S. commercial footprint exceeding 4,000 hospitals, an expanding patent portfolio, and 40 field sales representatives, while also outlining extensive regulatory, competitive, cybersecurity, operational and indebtedness risks, including revenue and liquidity covenants under a senior secured term loan.
Sanara MedTech Inc. reported strong 2025 growth with net revenue of $103.1 million, up 19% from 2024, and reaffirmed 2026 revenue guidance of $116–$121 million, implying 13%–17% additional growth. Revenue expansion was led by soft tissue repair products, especially CellerateRX Surgical, and supported by a broader distributor and facility network.
Adjusted EBITDA rose to $17.0 million from $9.1 million, and operating cash flow improved to $6.8 million. Gross margin reached 93% in Q4 2025. However, a strategic realignment and the discontinuation of Tissue Health Plus drove a $26.5 million noncash impairment and a full-year net loss of $37.6 million. Management highlights a focused surgical business, higher R&D investment, and long-term growth ambitions in the surgical market.